Boehringer Ingelheim and Microsoft Partner to Accelerate AI-Enabled Clinical Development

INGELHEIM, Germany and REDMOND, WA — In a major strategic initiative aimed at transforming biopharmaceutical research and development, Boehringer Ingelheim and Microsoft today announced a comprehensive collaboration to accelerate AI-enabled clinical trial design, disease modeling, and therapy deployment.

The joint venture centers on establishing a technical foundation for Digital Patient Twins —computational biophysical representations of human patients designed to predict disease progression and individual therapeutic responses. By merging Boehringer Ingelheim’s deep clinical and scientific expertise with Microsoft’s enterprise cloud infrastructure and advanced AI capabilities, the companies aim to streamline clinical trials, reduce dependency on traditional control groups, and deliver safe, effective medicines to patients faster.

Digital Patient Twins: Revolutionizing Clinical Trial Design
Clinical trials traditionally rely on physical control arms composed of patients who receive standard of care or placebos to benchmark the safety and efficacy of an experimental therapy. This process requires significant participant recruitment, extends trial timelines, and introduces ethical and operational complexities.

The collaboration between Boehringer Ingelheim and Microsoft directly addresses these hurdles by building predictive Digital Patient Twins. These computational models incorporate clinical trial historical data, real-world evidence (RWE), biomarker profiles, and longitudinal patient health records to construct virtual patient cohorts.

• The joint research initiative focuses on three core pillars:

  Disease-Progression Modeling: Simulating biological mechanisms to project how chronic and acute diseases evolve over time across diverse patient populations

• Predictive Outcome Modeling: Predicting clinical endpoints, adverse events, and therapeutic responses under varying dosage and treatment scenarios

• Advanced Trial Simulation: Utilizing synthetic and hybrid control arms—combining existing clinical data with virtual patient models to replace or supplement traditional human control groups

Initial Focus on Lung Health; Executive Leadership Perspective
To establish scientific validity and technical feasibility, Boehringer Ingelheim and Microsoft will begin prototyping and evidence generation across specific therapeutic areas, starting with lung health.

Boehringer Ingelheim holds an established global leadership position in respiratory medicine, particularly in pulmonary fibrosis, asthma, and chronic obstructive pulmonary disease (COPD). Applying Digital Patient Twins to lung health will allow researchers to model complex respiratory mechanics and tissue remodeling in silico. The collaboration with Boehringer Ingelheim brings together pharmaceutical and scientific expertise with Microsoft’s capabilities in AI and engineering.

Germany is home to world-class pharmaceutical research and development. Together, we want to explore how technology could open new opportunities for clinical research — Agnes Heftberger, Corporate Vice President and CEO of Microsoft Germany and Austria

Cross-Sector Potential: Animal Health and Enterprise Functions
Beyond human pharmaceuticals, the partnership outlines potential co development projects within Boehringer Ingelheim Animal Health—one of the world’s largest veterinary therapeutics and vaccine providers.

Applying AI-driven predictive modeling to livestock and companion animal health promises to accelerate veterinary drug discovery, optimize target discovery for infectious livestock diseases, and improve therapeutic delivery. Furthermore, the collaboration will evaluate AI co-development opportunities across broader business functions, enhancing operational workflows, regulatory filing processes, and digital health ecosystem integrations.